Neurological disorder

Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A

Retrieved on: 
Thursday, July 29, 2021

The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.

Key Points: 
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement.
  • All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Olink: CORAL to use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases

Retrieved on: 
Tuesday, July 27, 2021

UPPSALA, Sweden, July 27, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Olink) (Nasdaq: OLK) today announced that CORAL, a new collaborative community of scientists, will use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases.

Key Points: 
  • UPPSALA, Sweden, July 27, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Olink) (Nasdaq: OLK) today announced that CORAL, a new collaborative community of scientists, will use the Olink Proteomics platform to identify novel protein biomarkers and biological mechanisms for neurological diseases.
  • CORAL is a new collaborative community of scientists that work on diverse neurological conditions studying blood and cerebrospinal fluid (CSF) on the Olink Proteomics platform to identify novel biomarkers and biological mechanisms for neurological diseases.
  • CORAL is a collaborative community of scientists that work on diverse neurological conditions studying blood and CSF to identify novel biomarkers and biological mechanisms for neurological diseases.
  • The purpose of CORAL is to accelerate the development of biomarkers and mechanisms for neurological diseases, starting from array-based proteomics up to validation and implementation in the clinic.

Myomo, Inc. Announces Participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021

Retrieved on: 
Friday, July 23, 2021

The event will consist of one-on-one virtual investor meetings.

Key Points: 
  • The event will consist of one-on-one virtual investor meetings.
  • Investors participating in the virtual conference who are interested in meeting with members of Myomos management team should contact their A.G.P.
  • Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis.
  • Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally.

NeurologyLive® Expands Strategic Alliance Partnership Program with Four New Partners

Retrieved on: 
Wednesday, July 14, 2021

CRANBURY, N.J., July 14, 2021 /PRNewswire/ --NeurologyLive, a multimedia platform dedicated to providing health care professionalswith direct access to expert-driven, practice-changing news and insights in neurology, welcomes Buffalo Neuroimaging Analysis Center, Ctrl M Health, National Headache Foundation, and ClusterBusters to its Strategic Alliance Partnership (SAP) program.

Key Points: 
  • CRANBURY, N.J., July 14, 2021 /PRNewswire/ --NeurologyLive, a multimedia platform dedicated to providing health care professionalswith direct access to expert-driven, practice-changing news and insights in neurology, welcomes Buffalo Neuroimaging Analysis Center, Ctrl M Health, National Headache Foundation, and ClusterBusters to its Strategic Alliance Partnership (SAP) program.
  • "Partnering with these incredible organizations allows us to strengthen our position within the neurological space," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of NeurologyLive.
  • "We look forward to working with our new partners and continuing to positively impact the science and practice of neurology by delivering up-to-date disease-specific news and clinical resources."
  • Through innovative research techniques and advanced neuroimaging bioinformatics, BNAC is extending the boundaries of knowledge in neurological disease.

Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis

Retrieved on: 
Wednesday, July 7, 2021

The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.

Key Points: 
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • For more information about the Company, please visit www.bioasis.us .
  • Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement.

Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders

Retrieved on: 
Wednesday, July 7, 2021

XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders.

Key Points: 
  • XEN1101 is a differentiated Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders.
  • Patient randomization has been completed, and topline data are anticipated in late September to mid-October 2021.
  • We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer

Retrieved on: 
Thursday, July 1, 2021

The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.

Key Points: 
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • For more information about the Company, please visit www.bioasis.us .
  • Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Bioasis Technologies Inc. and Oxyrane UK Ltd. enter into a Research Collaboration

Retrieved on: 
Wednesday, June 30, 2021

The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.

Key Points: 
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • On behalf of the Board of Directors of Oxyrane UK Ltd.
    Oxyrane is a venture funded, pre-clinical stage biotech company dedicated to developing Enzyme Replacement Therapies (ERTs) for Lysosomal Storage Diseases.
  • Oxyranes lead program is an Enzyme Replacement Therapy for Gaucher Disease that has demonstrated superior phamacodynamic effects in disease animal models.

Bioasis Technologies Announces Closing of Initial C$3,000,000 Funding by Lind Partners

Retrieved on: 
Tuesday, June 29, 2021

The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.

Key Points: 
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • For more information about the Company, please visit www.bioasis.us .
  • Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement.

Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

Retrieved on: 
Friday, June 25, 2021

The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.

Key Points: 
  • The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders.
  • The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.
  • For more information about the Company, please visit www.bioasis.us .
  • Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement.